Open access
Open access
Powered by Google Translator Translator

General Hematology

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

7 May, 2021 | 08:33h | UTC

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

 

Commentary on Twitter

 


What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest

5 May, 2021 | 08:37h | UTC

What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest – Science

 


Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

4 May, 2021 | 08:38h | UTC

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation – EP Europace

Commentary: EHRA Updates Its Popular ‘Practical’ NOAC Guide – TCTMD

 


Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

3 May, 2021 | 05:43h | UTC

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 – JAMA

Editorial: Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine – JAMA

See also: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention AND Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention

Related: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

 


Study on five million Swedes finds links between blood groups and disease risks

3 May, 2021 | 05:09h | UTC

News Release: Study on five million Swedes finds links between blood groups and disease risks – Karolinska Institutet

Original Study: An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk – eLife

 


RCT: Tranexamic acid for the prevention of blood loss after cesarean delivery – even though TA resulted in a significantly lower incidence of estimated blood loss, the clinical relevance of the findings was small

30 Apr, 2021 | 08:38h | UTC

Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery – New England Journal of Medicine

 

Commentaries on Twitter

 


AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

30 Apr, 2021 | 08:25h | UTC

Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – Stroke

News release: Guidance on treatment for rare blood clots and low platelets related to COVID-19 vaccine – American Heart Association

Related: ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

 


Review: COVID-19-associated coagulopathy and antithrombotic agents – In non-critically ill hospitalized patients, therapeutic dose anticoagulation may improve clinical outcomes. In critically ill patients, this same treatment does not improve outcomes, and prophylactic dose anticoagulation is recommended

29 Apr, 2021 | 08:46h | UTC

COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year – The Lancet Haematology

Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

 

Commentary on Twitter

 


M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

29 Apr, 2021 | 08:28h | UTC

Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis – Blood Advances

 


Systematic Review: Disease‐modifying treatments for primary autoimmune hemolytic anemia

28 Apr, 2021 | 08:09h | UTC

Disease‐modifying treatments for primary autoimmune haemolytic anaemia – Cochrane Library

Summary: Treatment for primary autoimmune haemolytic anaemia – Cochrane Library

 


RCT: Reduced dose direct oral anticoagulants may be a safer option to vitamin K antagonists in hemodialysis patients with atrial fibrillation

27 Apr, 2021 | 09:27h | UTC

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial – Journal of the American Society of Nephrology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

21 Apr, 2021 | 07:11h | UTC

ISTH Interim Guidance for the Diagnosis and Treatment on VaccineInduced Immune Thrombotic Thrombocytopenia (Updated 20 April, 2021) – International Society on Thrombosis and Haemostasis

See also: Diagnostic Flow Chart

 

Commentary on Twitter

 


Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

21 Apr, 2021 | 07:09h | UTC

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions – American Society of Hematology

 


COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

21 Apr, 2021 | 07:07h | UTC

COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets – European Medicines Agency

Commentary: Johnson & Johnson vaccine: EU regulator says blood clot very rare side effect – BBC

 

Commentary on Twitter

 


M-A: Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention

20 Apr, 2021 | 05:40h | UTC

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis – The Lancet

 

Commentary on Twitter

 


Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

18 Apr, 2021 | 21:43h | UTC

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination – New England Journal of Medicine

Commentaries: Researchers Offer Algorithm for Managing Thrombosis and Thrombocytopenia After COVID-19 Vaccination – NEJM Journal Watch AND Blood Clots After COVID-19 Vaccination Linked to Immune Response: UK Report – TCTMD AND People with rare blood clots after a COVID-19 jab share an uncommon immune response – ScienceNews

 


Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”

18 Apr, 2021 | 21:42h | UTC

SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – New England Journal of Medicine

 


COVID vaccines and blood clots: five key questions

18 Apr, 2021 | 21:40h | UTC

COVID vaccines and blood clots: five key questions – Nature

See also (podcast): Coronapod: could COVID vaccines cause blood clots? Here’s what the science says – Nature

 


Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

15 Apr, 2021 | 07:02h | UTC

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine

Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation

 


U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots

14 Apr, 2021 | 02:16h | UTC

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine – U.S. Food & Drug Administration

Commentaries: Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots – BMJ AND CDC and FDA recommend US pause use of Johnson & Johnson’s Covid-19 vaccine over blood clot concerns – CNN AND US halts J&J COVID vaccine after reports of blood clots – CIDRAP AND U.S. urges pause on use of Johnson & Johnson Covid-19 vaccine after rare blood clotting cases – CIDRAP

 


Why would a Covid vaccine cause rare blood clots? Researchers have found clues

14 Apr, 2021 | 02:14h | UTC

Why would a Covid vaccine cause rare blood clots? Researchers have found clues – STAT

Related: How could a COVID vaccine cause blood clots? Scientists race to investigate – Nature

 


Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

12 Apr, 2021 | 01:20h | UTC

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine – TCTMD

Study 1: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination – New England Journal of Medicine

Study 2: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination – New England Journal of Medicine

 


EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine

12 Apr, 2021 | 01:18h | UTC

EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine – Health Policy Watch

See also: Johnson & Johnson’s COVID-19 vaccine under scrutiny at EMA after 4 ‘serious cases’ of unusual blood clots – Fierce Pharma AND J&J COVID-19 vaccine under EU review over blood clots, AstraZeneca probe grows – Reuters

 


WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed

8 Apr, 2021 | 09:09h | UTC

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. The benefits of the vaccine continue to outweigh the risks for people who receive it.

8 Apr, 2021 | 09:07h | UTC

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets – European Medicines Agency

Commentaries: In rare instances, AstraZeneca’s Covid-19 vaccine linked to blood clots, regulators say – STAT AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 


Stay Updated in Your Specialty

No spam, just news.